A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Phase 3

CrovalimabA Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Sponsor:

Hoffmann-La Roche

Code:

NCT04958265

Conditions

Atypical Hemolytic Uremic Syndrome

Eligibility Criteria

Sex: All

Age: 28 - 17

Healthy Volunteers: Not accepted

Interventions

Crovalimab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-03. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2025-05-31.